2026– date –
-
Dapis Cyanobacteria: Dolastatin 15 anticancer source explained
UF Health USA Overview University of Florida College of Pharmacy researchers identified the marine cyanobacterial genus Dapis as the natural source of dolastatin 15, a potent anticancer compound. This research marks the first genomic cha... -
PD-(L)1×VEGF ADC: 87.5% ORR in SCLC patients at WCLC 2026
VCBeat China Overview Early clinical data presented at WCLC 2026 revealed that a combination therapy of a PD-(L)1×VEGF bispecific antibody and an ADC, developed by a Chinese firm, achieved an 87.5% objective response rate (ORR) in small ... -
Oral GLP-1 Agonists: Weight loss and HbA1c efficacy explained
Apps Script USA Overview Clinical data reviews have confirmed the effectiveness of oral GLP-1 receptor agonists in significantly lowering HbA1c levels and inducing modest weight loss. Crucially, strict adherence to pre-dosing fasting pro... -
Stanford Virtual Biotech: AI agents drug discovery specs 2026
DistilINFO USA Overview Stanford University School of Medicine researchers have unveiled a test of 'Virtual Biotech,' an innovative operational model where thousands of AI agents simulate the entire drug discovery workflow. This project ... -
Olpasiran: Novartis’ Phase 2b siRNA Lp(a) reduction results
Biomedical Science Letters South Korea Overview Novartis' investigational siRNA therapeutic, olpasiran, demonstrated remarkable efficacy in the Phase 2b OCEAN(a)-DOSE trial, reducing lipoprotein(a) (Lp(a)) levels by over 95% at high dose... -
MIT LNP Technique: Organ-specific RNA delivery method explained
MIT News USA Overview MIT researchers have developed a novel lipid nanoparticle (LNP) manufacturing technique that precisely controls particle size and shape, critical for targeted RNA drug delivery. This innovation significantly enhance... -
Exosome Delivery: 6-fold Paclitaxel concentration for GBM specs
Zuglueducation.com Unknown Overview Exosome-based drug delivery systems have achieved breakthrough results in a Phase I/II clinical trial for glioblastoma multiforme (GBM). Paclitaxel-loaded exosomes, derived from patient mesenchymal ste... -
NTS231: Nutshell Therapeutics’ AI-driven 24-month IND timeline
AllSci USA Overview Nutshell Therapeutics received U.S. FDA Investigational New Drug (IND) clearance for NTS231, a covalent allosteric molecular glue degrader of NRF2. Remarkably, this was achieved in just 24 months from target nominatio... -
ARO-DIMER-PA: Arrowhead’s Phase 1/2a siRNA knockdown specs
Cyagen Lab Notes USA Overview Arrowhead Pharmaceuticals announced promising interim Phase 1/2a clinical data for ARO-DIMER-PA, a novel dual-function RNAi therapeutic targeting cardiometabolic diseases. This single siRNA molecule simultan... -
South Korea: All-solid-state battery roadmap and 2030 goals
pv magazine Global South Korea Overview The South Korean government has launched a new 'Battery Industry Technology Roadmap' aiming for the commercialization of all-solid-state batteries by 2030 to regain market leadership. Key targets i...
